BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

707 related articles for article (PubMed ID: 30922328)

  • 1. Reduced protocadherin17 expression in leukemia stem cells: the clinical and biological effect in acute myeloid leukemia.
    Xu ZJ; Ma JC; Zhou JD; Wen XM; Yao DM; Zhang W; Ji RB; Wu DH; Tang LJ; Deng ZQ; Qian J; Lin J
    J Transl Med; 2019 Mar; 17(1):102. PubMed ID: 30922328
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High NCALD expression predicts poor prognosis of cytogenetic normal acute myeloid leukemia.
    Song Y; Zhang W; He X; Liu X; Yang P; Wang J; Hu K; Liu W; Zhang X; Jing H; Yuan X
    J Transl Med; 2019 May; 17(1):166. PubMed ID: 31109331
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High IL2RA mRNA expression is an independent adverse prognostic biomarker in core binding factor and intermediate-risk acute myeloid leukemia.
    Du W; He J; Zhou W; Shu S; Li J; Liu W; Deng Y; Lu C; Lin S; Ma Y; He Y; Zheng J; Zhu J; Bai L; Li X; Yao J; Hu D; Gu S; Li H; Guo A; Huang S; Feng X; Hu D
    J Transl Med; 2019 Jun; 17(1):191. PubMed ID: 31171000
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MicroRNA-9 promotes proliferation of leukemia cells in adult CD34-positive acute myeloid leukemia with normal karyotype by downregulation of Hes1.
    Tian C; You MJ; Yu Y; Zhu L; Zheng G; Zhang Y
    Tumour Biol; 2016 Jun; 37(6):7461-71. PubMed ID: 26678889
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and Biological Implications of Mutational Spectrum in Acute Myeloid Leukemia of FAB Subtypes M0 and M1.
    Cheng Z; Dai Y; Pang Y; Jiao Y; Zhao H; Wu S; Zhang L; Zhang Y; Wang X; Wang L; Ma D; Qin T; Hu N; Zhang Y; Hu K; Zhang Q; Shi J; Fu L
    Cell Physiol Biochem; 2018; 47(5):1853-1861. PubMed ID: 29961066
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic methylation markers for overall survival in cytogenetically normal patients with acute myeloid leukemia treated on SWOG trials.
    Qu X; Othus M; Davison J; Wu Y; Yan L; Meshinchi S; Ostronoff F; Estey EH; Radich JP; Erba HP; Appelbaum FR; Fang M
    Cancer; 2017 Jul; 123(13):2472-2481. PubMed ID: 28222251
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of a leukemic stem cell gene expression signature with clinical outcomes in acute myeloid leukemia.
    Gentles AJ; Plevritis SK; Majeti R; Alizadeh AA
    JAMA; 2010 Dec; 304(24):2706-15. PubMed ID: 21177505
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gene expression profiling in the leukemic stem cell-enriched CD34+ fraction identifies target genes that predict prognosis in normal karyotype AML.
    de Jonge HJ; Woolthuis CM; Vos AZ; Mulder A; van den Berg E; Kluin PM; van der Weide K; de Bont ES; Huls G; Vellenga E; Schuringa JJ
    Leukemia; 2011 Dec; 25(12):1825-33. PubMed ID: 21760593
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD34 expression predicts an adverse outcome in patients with NPM1-positive acute myeloid leukemia.
    Dang H; Chen Y; Kamel-Reid S; Brandwein J; Chang H
    Hum Pathol; 2013 Oct; 44(10):2038-46. PubMed ID: 23701943
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PCDH17 functions as a common tumor suppressor gene in acute leukemia and its transcriptional downregulation is mediated primarily by aberrant histone acetylation, not DNA methylation.
    Thanh Nha Uyen L; Amano Y; Al-Kzayer LFY; Kubota N; Kobayashi J; Nakazawa Y; Koike K; Sakashita K
    Int J Hematol; 2020 Mar; 111(3):451-462. PubMed ID: 31865541
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systematic computation with functional gene-sets among leukemic and hematopoietic stem cells reveals a favorable prognostic signature for acute myeloid leukemia.
    Yang XH; Li M; Wang B; Zhu W; Desgardin A; Onel K; de Jong J; Chen J; Chen L; Cunningham JM
    BMC Bioinformatics; 2015 Mar; 16():97. PubMed ID: 25887548
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD9 in acute myeloid leukemia: Prognostic role and usefulness to target leukemic stem cells.
    Touzet L; Dumezy F; Roumier C; Berthon C; Bories C; Quesnel B; Preudhomme C; Boyer T
    Cancer Med; 2019 Mar; 8(3):1279-1288. PubMed ID: 30740913
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Methylation-associated DOK1 and DOK2 down-regulation: Potential biomarkers for predicting adverse prognosis in acute myeloid leukemia.
    He PF; Xu ZJ; Zhou JD; Li XX; Zhang W; Wu DH; Zhang ZH; Lian XY; Yao XY; Deng ZQ; Lin J; Qian J
    J Cell Physiol; 2018 Sep; 233(9):6604-6614. PubMed ID: 29150948
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MRP1 protein expression in leukemic stem cells as a negative prognostic marker in acute myeloid leukemia patients.
    Paprocka M; Bielawska-Pohl A; Rossowska J; Krawczenko A; Duś D; Kiełbiński M; Haus O; Podolak-Dawidziak M; Kuliczkowski K
    Eur J Haematol; 2017 Nov; 99(5):415-422. PubMed ID: 28805931
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Decreased DNA methylation in acute myeloid leukemia patients with DNMT3A mutations and prognostic implications of DNA methylation.
    Hájková H; Marková J; Haškovec C; Sárová I; Fuchs O; Kostečka A; Cetkovský P; Michalová K; Schwarz J
    Leuk Res; 2012 Sep; 36(9):1128-33. PubMed ID: 22749068
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overexpression of IL-1 receptor accessory protein in stem and progenitor cells and outcome correlation in AML and MDS.
    Barreyro L; Will B; Bartholdy B; Zhou L; Todorova TI; Stanley RF; Ben-Neriah S; Montagna C; Parekh S; Pellagatti A; Boultwood J; Paietta E; Ketterling RP; Cripe L; Fernandez HF; Greenberg PL; Tallman MS; Steidl C; Mitsiades CS; Verma A; Steidl U
    Blood; 2012 Aug; 120(6):1290-8. PubMed ID: 22723552
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A stem cell-like gene expression signature associates with inferior outcomes and a distinct microRNA expression profile in adults with primary cytogenetically normal acute myeloid leukemia.
    Metzeler KH; Maharry K; Kohlschmidt J; Volinia S; Mrózek K; Becker H; Nicolet D; Whitman SP; Mendler JH; Schwind S; Eisfeld AK; Wu YZ; Powell BL; Carter TH; Wetzler M; Kolitz JE; Baer MR; Carroll AJ; Stone RM; Caligiuri MA; Marcucci G; Bloomfield CD
    Leukemia; 2013 Oct; 27(10):2023-31. PubMed ID: 23765227
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of biomarkers for acute leukemia via machine learning-based stemness index.
    Zhang Y; Liu D; Li F; Zhao Z; Liu X; Gao D; Zhang Y; Li H
    Gene; 2021 Dec; 804():145903. PubMed ID: 34411647
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early B-cell factor 3 (EBF3) is a novel tumor suppressor gene with promoter hypermethylation in pediatric acute myeloid leukemia.
    Tao YF; Xu LX; Lu J; Hu SY; Fang F; Cao L; Xiao PF; Du XJ; Sun LC; Li ZH; Wang NN; Su GH; Li YH; Li G; Zhao H; Li YP; Xu YY; Zhou HT; Wu Y; Jin MF; Liu L; Zhu XM; Ni J; Wang J; Xing F; Zhao WL; Pan J
    J Exp Clin Cancer Res; 2015 Jan; 34(1):4. PubMed ID: 25609158
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protocadherin17 Promoter Methylation is a Potential Predictive Biomarker in Clear Cell Renal Cell Carcinoma.
    Lin YL; Gui SL; Guo H; Ma JG; Li WP
    Med Sci Monit; 2015 Sep; 21():2870-6. PubMed ID: 26404644
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.